European Journal of Pediatrics

, Volume 138, Issue 2, pp 151–153 | Cite as

Variability of serum indomethacin concentrations after oral and intravenous administration to preterm infants

  • R. Mrongovius
  • H. Imbeck
  • L. Wille
  • H. Müller
  • H. W. Seyberth
Original Investigations

Abstract

Fifteen preterm infants with patent ductus arteriosus and respiratory distress syndrome were given indomethacin (0.2 mg/kg) at 12 h intervals up to three times, either orally or intravenously, in an uncontrolled, non-randomized study. Serum indomethacin concentrations were determined in blood samples taken 12 h after dosing. There was considerable variability in the serum indomethacin concentrations, especially after oral administration, although the mean concentrations after each of the three doses were similar after both oral and intravenous administration. The frequency of closures and transient closures of the ductus arteriosus was also similar for both routes of administration. There was, however, no relation between concentration and effect in individual patients. The sustained exposure to indomethacin which appears to be necessary for ductal closure can sometimes be attained by oral administration.

Key words

Indomethacin Preterm infants Patent ductus arteriosus 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alpert BS, Lewins MJ, Rowland DW, Grant MJA, Olley PM, Soldin SJ, Swyer PR, Coceani F, Rowe RD (1979) Plasma indomethacin levels in preterm newborn infants with symptomatic patent ductus arteriosus-clinical and echocardiographic assessments of response. J Pediatr 95:578–582Google Scholar
  2. Anonymous (1981) Patent ductus and indomethacin. Lancet I:877Google Scholar
  3. Bhat R, Vidyasagar D, Fisher E, Hastreiter A, Ramirez JL, Burns L, Evans M (1980) Pharmacokinetics of oral and intravenous indomethacin in preterm infants. Dev Pharmacol Ther 1:101–110Google Scholar
  4. Bianchetti G, Monin P, Marchal F, Dubruc C, Boutroy MJ, Morselli PL, Vert P (1980) Pharmacolinetics of indomethacin in the premature infant. Dev Pharmacol Ther 1:111–124Google Scholar
  5. Brash AR, Hickey DE, Graham TP, Stahlman MT, Oates JA, Cotton RB (1981) Pharmacokinetics of indomethacin in the neonate. Relation of plasma indomethacin levels to response of the ductus arteriosus. N Engl J Med 305:67–72Google Scholar
  6. Erlenmaier T, Müller H, Seyberth HW (1979) Combined capillary column gas chromatography—mass spectrometric method for the quantitative analysis of urinary prostaglandins. J Chromatogr 163:289–293Google Scholar
  7. Evans MA, Bhat R, Vidyasagar D, Vadapalli M, Fisher E, Hastreiter A (1979) Gestational age and indomethacin elimination in the neonate. Clin Pharmacol Ther 26:746–751Google Scholar
  8. Evans M, Bhat R, Vidyasagar D, Patel M, Hastreiter A (1981) A comparison of oral and intravenous indomethacin dispositions in the premature infant with patent ductus arteriosus. Pediatr Pharmacol 1:251–258Google Scholar
  9. Giedion A, Haefliger H, Dangel P (1973) Acute pulmonary X-ray changes in hyaline membrane disease treated with artificial ventilation and positive end-expiratory pressure (PEP). Pediatr Radiol 1:145–152Google Scholar
  10. Green TP, Thompson TR, Johnson D, Lock JE (1981) Furosemide use in premature infants and appearance of patent ductus arteriosus. Am J Dis Child 135:239–243Google Scholar
  11. Nestrud RM, Hill DE, Arrington RW, Beard AG, Dungan WT, Lau P-Y, Norton JB, Readinger RI (1980) Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Dev Pharmacol Ther 1:125–136Google Scholar
  12. Olley PM, Coceani F (1981) Prostaglandins and ductus arteriosus. Ann Rev Med 32:375–385Google Scholar
  13. Petersen S, Christensen NG, Jensen KM, Ryssing E (1981) Serum indomethacin concentrations after intravenous administration to preterm infants with patent ductus arteriosus. Acta Paediatr Scand 70:729–733Google Scholar
  14. Seyberth HW, Müller H, Erlenmaier T, Mrongovius R (1980) Mass spectrometric determination of urinary prostaglandins in preterm infants. The basis for an effective and safe therapeutic regimen for the pharmacological closure of the ductus arterious. Eur J Clin Pharmacol 18:89–93Google Scholar
  15. Seyberth HW, Müller H, Wille L, Plückthun H, Wolf D, Ulmer HE (1982) Recovery of prostaglandin production associated with reopening of the patent ductus arteriosus after indomethacin treatment in preterm infants with respiratory distress syndrome. Pediatr Pharmacol 2: (in press)Google Scholar
  16. Shaw LD, Barrett CT, Friedman WF (1981) The relationship between total fluid administration and indomethacin dose needed to close the ductus arteriosus (Abstract). Pediatr Res 15:680Google Scholar
  17. Thalji AA, Carr I, Yeh TF, Raval D, Luken JA, Pildes RS (1980) Pharmacokinetics of intravenously administered indomethacin in premature infants. J Pediatr 97:995–1000Google Scholar
  18. Vert P, Bianchetti G, Marchal F, Monin P, Morselli PL (1980) Effectiveness and pharmacokinetics of indomethacin in premature newborns with patent ductus arteriosus. Eur J Clin Pharmacol 18:83–88Google Scholar
  19. Yaffe SJ, Friedman WF, Rogers D, Lang P, Ragni M, Saccar C (1980) The disposition of indomethacin in preterm babies. J Pediatr 97:1001–1006Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • R. Mrongovius
    • 1
  • H. Imbeck
    • 1
  • L. Wille
    • 2
  • H. Müller
    • 2
  • H. W. Seyberth
    • 2
  1. 1.Pharmakologisches Institut der Universität HeidelbergHeidelbergFederal Republic of Germany
  2. 2.Universitäts-KinderklinikHeidelbergFederal Republic of Germany

Personalised recommendations